Market Overview:
The global azacitidine injection market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of hematological disorders, rising awareness about azacitidine therapy, and growing number of clinical trials for azacitidine. Based on type, the global azacitidine injection market is segmented into 50mg and 100mg. The 100mg segment is expected to account for a larger share of the market than the 50mg segment during the forecast period. This can be attributed to its higher efficacy in treating hematological disorders as compared with 50mg. Based on application, the global azacitidine injection market is divided into higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and others. The AML segment is expected to account for a larger share of the market than other segments during the forecast period owing to its high prevalence and unmet needs in terms of treatment options.
Product Definition:
Azacitidine Injection is used to treat myelodysplastic syndromes (MDS), a group of blood disorders that affect the bone marrow and blood. Azacitidine belongs to a class of drugs called hypomethylating agents. It works by slowing or stopping the growth of cancer cells in the body.
50mg:
50mg is used for the treatment of cancer and HIV aids. This enzyme is responsible for the conversion of ribonucleotide to deoxythymidine nucleotides. The inhibition results in increased levels of dTTP, which then leads to increased synthesis of DNA chains and reduced breakdown.
100mg:
Azacitidine is an antibiotic used in the treatment of acute bacterial skin and soft tissue infections. The drug has a wide range of applications including respiratory tract infections, urinary tract infections, and bone/joint infection. Azacitidine is also used off-label for treatment of community-acquired pneumonia as well as ventilator-associated pneumonia (Hospital Acquired Pneumonia).
Application Insights:
The application segment includes higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and others. In 2017, the MDS segment dominated the market with a share of over 50% in North America. The growth is attributed to an increase in number of patients suffering from MDS across the globe. According to data published by NCBI, around 1250 new cases are reported every year globally while about 1750 new cases are diagnosed annually in North America alone.
Increasing incidence of cancer coupled with rising geriatric population across the globe is expected to drive demand for azacitidine injection over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and increasing healthcare expenditure are some of the major factors contributing to its growth. In addition, rise in awareness about available treatment options is expected to drive regional demand for azacitidine over the forecast period.
Asia Pacific is anticipated to witness fastest CAGR during the forecast period owing to rising incidence rates of MDS/myelodysplasia coupled with improving healthcare infrastructure and economic development in emerging countries such as China & India & Pakistan etcetera.
Growth Factors:
- Increasing incidence of myelodysplastic syndromes (MDS)
- Rising geriatric population
- Growing demand for targeted cancer therapies
- Technological advancements in azacitidine therapy
- increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Azacitidine Injection Market Research Report
By Type
50mg, 100mg
By Application
Higher-risk myelodysplastic syndromes (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Others
By Companies
Celgene, Mylan, Shilpa Medicare, Accord Healthcare, Natco Pharma, Dr. Reddy's Laboratories, CTTQ, Huiyu Pharmaceutital, Eurohealth
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
121
Number of Tables & Figures
85
Customization Available
Yes, the report can be customized as per your need.
Global Azacitidine Injection Market Report Segments:
The global Azacitidine Injection market is segmented on the basis of:
Types
50mg, 100mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Higher-risk myelodysplastic syndromes (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celgene
- Mylan
- Shilpa Medicare
- Accord Healthcare
- Natco Pharma
- Dr. Reddy's Laboratories
- CTTQ
- Huiyu Pharmaceutital
- Eurohealth
Highlights of The Azacitidine Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 50mg
- 100mg
- By Application:
- Higher-risk myelodysplastic syndromes (MDS)
- Acute Myeloid Leukemia (AML)
- Chronic Myelomonocytic Leukemia (CMML)
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Azacitidine Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Azacitidine injection is a medication used to treat cancer. It works by stopping the growth of cancer cells.
Some of the major players in the azacitidine injection market are Celgene, Mylan, Shilpa Medicare, Accord Healthcare, Natco Pharma, Dr. Reddy's Laboratories, CTTQ, Huiyu Pharmaceutital, Eurohealth.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Azacitidine Injection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Azacitidine Injection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Azacitidine Injection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Azacitidine Injection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Azacitidine Injection Market Size & Forecast, 2020-2028
4.5.1 Azacitidine Injection Market Size and Y-o-Y Growth
4.5.2 Azacitidine Injection Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 50mg
5.2.2 100mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Higher-risk myelodysplastic syndromes (MDS)
6.2.2 Acute Myeloid Leukemia (AML)
6.2.3 Chronic Myelomonocytic Leukemia (CMML)
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Azacitidine Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Azacitidine Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 50mg
9.6.2 100mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Higher-risk myelodysplastic syndromes (MDS)
9.10.2 Acute Myeloid Leukemia (AML)
9.10.3 Chronic Myelomonocytic Leukemia (CMML)
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 50mg
10.6.2 100mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Higher-risk myelodysplastic syndromes (MDS)
10.10.2 Acute Myeloid Leukemia (AML)
10.10.3 Chronic Myelomonocytic Leukemia (CMML)
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 50mg
11.6.2 100mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Higher-risk myelodysplastic syndromes (MDS)
11.10.2 Acute Myeloid Leukemia (AML)
11.10.3 Chronic Myelomonocytic Leukemia (CMML)
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 50mg
12.6.2 100mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Higher-risk myelodysplastic syndromes (MDS)
12.10.2 Acute Myeloid Leukemia (AML)
12.10.3 Chronic Myelomonocytic Leukemia (CMML)
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 50mg
13.6.2 100mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Higher-risk myelodysplastic syndromes (MDS)
13.10.2 Acute Myeloid Leukemia (AML)
13.10.3 Chronic Myelomonocytic Leukemia (CMML)
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Azacitidine Injection Market: Competitive Dashboard
14.2 Global Azacitidine Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Celgene
14.3.2 Mylan
14.3.3 Shilpa Medicare
14.3.4 Accord Healthcare
14.3.5 Natco Pharma
14.3.6 Dr. Reddy's Laboratories
14.3.7 CTTQ
14.3.8 Huiyu Pharmaceutital
14.3.9 Eurohealth
